Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.40 |
| ▸ | USP2 | O75604 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17949199 | 1.00 | TSHR (0.48) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL29529953 | 1.00 | TSHR (0.48) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL17949198 | 1.00 | TSHR (0.48) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL29529870 | 1.00 | TSHR (0.48) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL30833428 | 1.00 | TSHR (0.48) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| Trifluoroacetic Acid SCHEMBL29529844 | 0.97 | TSHR (0.47) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| Trifluoroacetic Acid SCHEMBL17942549 | 0.97 | TSHR (0.47) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL17942446 | 0.93 | TSHR (0.52) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL29529666 | 0.92 | TSHR (0.47) | TSHRNPC1CYP3A4NR1I2CACNA1B | |
| SCHEMBL17949337 | 0.92 | TSHR (0.47) | TSHRNPC1CYP3A4NR1I2CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200345716-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-20200345716-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-10758525-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10758525-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200113887-A9 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200113887-A9 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190269669-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190269669-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2019-09-05 | — | — | US | disclosed |
| US-9925177-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925177-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925177-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113887-A9 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-10758525-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-20190269669-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-20200345716-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | TSHR 3993/4885NPC1 2311/4885CYP3A4 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.